Trial Profile
Immunological Basis for Mepolizumab Activity in COPD
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Apr 2023
Price :
$35
*
At a glance
- Drugs Mepolizumab (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- 05 Apr 2023 Planned primary completion date changed from 1 Feb 2024 to 1 Apr 2024.
- 05 Apr 2023 Planned initiation date changed from 1 Oct 2022 to 1 Apr 2023.
- 20 Oct 2022 Planned primary completion date changed from 1 May 2024 to 1 Feb 2024.